Skip to main content
All lobbying filings

VERTEX PHARMACEUTICALS INCORPORATED

Lobbying for VERTEX PHARMACEUTICALS INCORPORATED

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2025 · Massachusetts · House · Senate · $1,600,000.00 expenses · posted Apr 18, 2025

Official filing document

 Bills named in this filing 3
 Lobbying activity 4
Medicare/Medicaid

Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.

Taxation/Internal Revenue Code

Issues related to corporate tax reform.

Budget/Appropriations

Education about non-opioid pain therapies and patient access to non-opioid medicines, education on alternative funding programs, education on the Million Veteran Program at the VA.

Health Issues

Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (S.864); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem